Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 13/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.40 |
| ▸ | CYP21A2 | P08686 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 6/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5633179 | 1.00 | F10 (0.48) | F10ALDH1A1ALOX15TSHRCYP17A1 | |
| SCHEMBL5632000 | 0.92 | ALDH1A1 (0.49) | F10ALDH1A1ALOX15TSHRF2 | |
| SCHEMBL5632002 | 0.92 | ALDH1A1 (0.49) | F10ALDH1A1ALOX15TSHRF2 | |
| SCHEMBL7114329 | 0.89 | F10 (0.51) | F10ALDH1A1ALOX15TSHRCYP17A1 | |
| SCHEMBL7114331 | 0.89 | F10 (0.51) | F10ALDH1A1ALOX15TSHRCYP17A1 | |
| SCHEMBL5633166 | 0.81 | ALDH1A1 (0.57) | F10ALDH1A1ALOX15TSHR | |
| SCHEMBL5633167 | 0.81 | ALDH1A1 (0.57) | F10ALDH1A1ALOX15TSHR | |
| SCHEMBL7113715 | 0.78 | F10 (0.55) | F10ALDH1A1ALOX15TSHRCYP17A1 | |
| SCHEMBL7113722 | 0.78 | F10 (0.55) | F10ALDH1A1ALOX15TSHRCYP17A1 | |
| SCHEMBL7115313 | 0.75 | F10 (0.44) | F10CYP17A1CYP21A2CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030207882-A1 | Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents | ZENECA LIMITED | 2003-11-06 | — | — | US | claimed |
| US-7173025-B1 | Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents | ZENECA LIMITED (GB) | 2007-02-06 | — | — | US | disclosed |
| US-20030207882-A1 | Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents | ZENECA LIMITED | 2003-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207882-A1 | Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents | F2, SERPINC1, F11 | F10 8/4885ALDH1A1 753/4885ALOX15 1252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.